Factor Xa inhibitors are the most likely new oral anticoagulants to reach the market. The class is led by Bayer/J&J's rivaroxaban (Xarelto), approved in Europe but not yet in the US. Seven other agents are in development and will compete for a >$5BN opportunity. To reach this lofty goal, Xarelto and its kin must demonstrate a clear clinical benefit that so far has been elusive. This report discusses the market, the competitors and the differentiating factors.
Note: Product cover images may vary from those shown